利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

22 条记录 (耗时 0.023 秒)

    Internalizing anti-CD-74 antibodies and methods of use
    1.
    发明申请
    Internalizing anti-CD-74 antibodies and methods of use 有权
    内化抗CD-74抗体及其使用方法

    公开(公告)号：US20040115193A1

    公开(公告)日：2004-06-17

    申请号：US10377122

    申请日：2003-03-03

    申请人： Immunomedics, Inc.

    发明人： Hans J. Hansen ,  Shui-on Leung ,  Zhengxing Qu ,  David M. Goldenberg

    IPC分类号： A61K039/395 ,  C07K016/44

    CPC分类号： A61K45/06 ,  A61K38/00 ,  A61K47/6849 ,  A61K51/1027 ,  A61K2039/505 ,  C07K16/2833 ,  C07K16/2896 ,  C07K2317/24 ,  C07K2317/77

    摘要： The present invention provides humanized, chimeric and human anti-CD74 antibodies, CD74 antibody fusion proteins, immunoconjugates, vaccines and bispecific that bind to CD74, the major histocompatibility complex (MHC) class-II invariant chain, Ii, which is useful for the treatment and diagnosis of B-cell disorders, such as B-cell malignancies, other malignancies in which the cells are reactive with CD74, and autoimmune diseases, and methods of treatment and diagnosis.

    摘要翻译： 本发明提供人源化，嵌合和人抗CD74抗体，CD74抗体融合蛋白，免疫缀合物，疫苗和结合CD74的双特异性，主要组织相容性复合体（MHC）II类不变链I 1可用于治疗 B细胞病变，B细胞恶性肿瘤，其他细胞与CD74反应的其他恶性肿瘤，以及自身免疫性疾病以及治疗和诊断方法的诊断。

    Cytotoxic therapy
    2.
    发明申请
    Cytotoxic therapy 审中-公开
    细胞毒性治疗

    公开(公告)号：US20030170175A1

    公开(公告)日：2003-09-11

    申请号：US10318366

    申请日：2002-12-13

    申请人： IMMUNOMEDICS, INC.

    发明人： David M. Goldenberg

    IPC分类号： A61K051/00 ,  A61K039/395 ,  A61K039/40 ,  A61K038/19

    CPC分类号： B82Y5/00 ,  A61K39/44 ,  A61K47/6813 ,  A61K51/1084 ,  A61K2039/505 ,  A61K2121/00 ,  C07K16/28 ,  C07K16/3007 ,  C07K2317/31 ,  A61K2300/00

    摘要： Anticancer, antimicrobial and autoimmune disease, and anti-organ rejection therapy using cytotoxic agents is improved using cytokines to prevent, mitigate or reverse adverse radiation-induced or drug-induced toxicity, especially to hematopoietic cells. Cytotoxic agents can include radioisotopes, drugs, toxins and even unconjugated cytotoxic antibodies. A preferred cytokine is IL-1. Higher doses of cytotoxic agents can be administered and tolerated by the patient and dose-limiting marrow toxicity can be prevented, palliated or reversed using adjunct cytokine therapy. Polyspecific immunoconjugates and antibody composites that bind a multidrug transporter protein and an antigen associated with a tumor or infectious agent are used to overcome the multidrug resistant phenotype. These immunoconjugates and composites also can be used diagnostically to determine whether the failure of traditional chemotherapy is due to the presence of multidrug resistant tumor cells, multidrug resistant HIV-infected cells or multidrug resistant infectious agents.

    摘要翻译： 使用细胞因子来预防，减轻或逆转不利的放射诱导或药物诱导的毒性，特别是造血细胞，改善抗癌，抗微生物和自身免疫疾病以及使用细胞毒性剂的抗器官排斥治疗。 细胞毒剂可以包括放射性同位素，药物，毒素，甚至是非共轭的细胞毒性抗体。 优选的细胞因子是IL-1。 更高剂量的细胞毒性剂可以由患者施用和耐受，并且可以使用辅助细胞因子治疗来预防，缓解或逆转剂量限制性骨髓毒性。 结合多药转运蛋白和与肿瘤或感染因子相关的抗原的多特异性免疫偶联物和抗体复合物被用于克服多药耐药表型。 这些免疫缀合物和复合物也可用于诊断，以确定传统化学疗法的失败是否由于存在多药耐药性肿瘤细胞，多药耐药HIV感染细胞或多重耐药感染剂。

    Polyspecific immunoconjugates and antibody composites for targeting the multidrug resistant phenotype
    5.
    发明申请
    Polyspecific immunoconjugates and antibody composites for targeting the multidrug resistant phenotype 失效
    用于靶向多药耐药表型的多特异性免疫偶联物和抗体复合物

    公开(公告)号：US20040071692A1

    公开(公告)日：2004-04-15

    申请号：US10680160

    申请日：2003-10-08

    申请人： IMMUNOMEDICS, INC.

    发明人： David M. Goldenberg

    IPC分类号： A61K039/395 ,  C07K016/46

    CPC分类号： B82Y5/00 ,  A61K47/68 ,  A61K47/6898 ,  A61K51/1084 ,  A61K51/1093 ,  A61K2039/505 ,  C07K16/28 ,  C07K16/3007 ,  C07K2317/31

    摘要： Polyspecific immunoconjugates and antibody composites that bind a multidrug transporter protein and an antigen associated with a tumor or infectious agent are used to overcome the multidrug resistant phenotype. These immunoconjugates and composites also can be used diagnostically to determine whether the failure of traditional chemotherapy is due to the presence of multidrug resistant tumor cells, multidrug resistant HIV-infected cells or multidrug resistant infectious agents.

    摘要翻译： 结合多药转运蛋白和与肿瘤或感染因子相关的抗原的多特异性免疫偶联物和抗体复合物被用于克服多药耐药表型。 这些免疫缀合物和复合物也可用于诊断，以确定传统化学疗法的失败是否由于存在多药耐药性肿瘤细胞，多药耐药HIV感染细胞或多重耐药感染剂。

    Immunotherapy of B-cell malignancies using anti-CD22 antibodies
    6.
    发明申请
    Immunotherapy of B-cell malignancies using anti-CD22 antibodies 有权

    公开(公告)号：US20030124058A1

    公开(公告)日：2003-07-03

    申请号：US10314330

    申请日：2002-12-09

    申请人： Immunomedics, Inc.

    发明人： David M. Goldenberg

    IPC分类号： A61K051/00 ,  A61K039/395 ,  A61K038/19

    CPC分类号： C07K16/2803 ,  A61K38/00 ,  A61K39/395 ,  A61K39/39558 ,  A61K2039/505 ,  A61K2039/507 ,  C07K16/2887 ,  A61K2300/00

    摘要： B-cell malignancies, such as the B-cell subtype of non-Hodgkin's lymphoma and chronic lymphocytic leukemia, are significant contributors to cancer mortality. The response of B-cell malignancies to various forms of treatment is mixed. Traditional methods of treating B-cell malignancies, including chemotherapy and radiotherapy, have limited utility due to toxic side effects. Immunotherapy with anti-CD20 antibodies have also provided limited success. The use of antibodies that bind with the CD22 or CD19 antigen, however, provides an effective means to treat B-cell malignancies such as indolent and aggressive forms of B-cell lymphomas, and acute and chronic forms of lymphatic leukemias. Moreover, immunotherapy with anti-CD22 and/or anti-CD19 antibodies requires comparatively low doses of antibody protein, and can be used effectively in multimodal therapies.

    Immunotherapy for chronic myelocytic leukemia
    9.
    发明申请
    Immunotherapy for chronic myelocytic leukemia 有权
    免疫治疗慢性骨髓性白血病

    公开(公告)号：US20040213796A1

    公开(公告)日：2004-10-28

    申请号：US10853150

    申请日：2004-05-26

    申请人： Immunomedics, Inc.

    发明人： David M. Goldenberg ,  Hans J. Hansen

    IPC分类号： A61K039/395

    CPC分类号： C07K16/2803

    摘要： Immunotherapy utilizing naked anti-granulocyte antibodies provides an effective means for treating chronic myelocytic leukemia (CML). Such antibodies can be administered alone or in combination with other therapies, such as immunoconjugates or chemotherapeutics. In either format, an effective therapy for treating CML is provided, which avoids the toxic side-effects typically associated with cancer therapy. The disclosed immunotherapy also is effective for treating acute myelocytic leukemia (AML) when co-administered with inducing agents which induce expression of antigens minimally displayed on the surface of myeloblasts.

    摘要翻译： 使用裸抗粒细胞抗体的免疫治疗提供治疗慢性骨髓性白血病（CML）的有效手段。 这样的抗体可以单独施用或与其它疗法组合施用，例如免疫缀合物或化学治疗剂。 以任一格式，提供治疗CML的有效治疗方法，其避免通常与癌症治疗相关的毒副作用。 当与诱导表达共同施用时，所公开的免疫治疗也可有效治疗急性髓细胞性白血病（AML），所述诱导剂诱导表达最低限度地显示在原粒细胞表面上。

    Polymeric delivery systems
    10.
    发明申请
    Polymeric delivery systems 审中-公开
    聚合物输送系统

    公开(公告)号：US20040043030A1

    公开(公告)日：2004-03-04

    申请号：US10456580

    申请日：2003-06-09

    申请人： Immunomedics, Inc.

    发明人： Gary L. Griffiths ,  David M. Goldenberg ,  Hans J. Hansen

    IPC分类号： G01N033/574 ,  A61K039/395

    CPC分类号： A61K51/10 ,  A61K47/645 ,  A61K47/646 ,  A61K47/6897 ,  A61K51/083 ,  A61K51/088 ,  B82Y5/00

    摘要： The present invention relates to a method of targeting an agent towards a targeting site in a tissue comprising administering a multi-specific antibody or antibody fragment comprising a targeting arm and a capture arm that binds to a polymer conjugate, and administering a polymer conjugate to the tissue. The present invention also relates to a kit for targeting a target site within a comprising a multi-specific antibody or antibody fragment comprising a targeting arm and a capture arm that binds to a polymer conjugate, and a polymer conjugate.

    摘要翻译： 本发明涉及将药物靶向组织中的靶向部位的方法，包括施用多特异性抗体或抗体片段，所述多特异性抗体或抗体片段包含与聚合物缀合物结合的靶向臂和捕获臂，以及向所述聚合物缀合物施用聚合物缀合物 组织。 本发明还涉及用于靶向包含多特异性抗体或抗体片段的靶位点的试剂盒，所述多特异性抗体或抗体片段包含与聚合物缀合物结合的靶向臂和捕获臂，以及聚合物缀合物。